Opzelura Cream (Ruxolitinib 1.5%)

Prescription Topical International (available in India)

Incyte · International (available in India)

Price: ₹3000–₹6000

Description

Opzelura contains ruxolitinib 1.5%, the first topical JAK (Janus kinase) inhibitor approved for atopic dermatitis and non-segmental vitiligo. It blocks JAK1/JAK2 signalling, reducing inflammatory cytokine-driven itch and inflammation. Represents a new class of steroid-free topical therapy.

Active Compounds

Ruxolitinib

Active ingredient — topical JAK1/JAK2 inhibitor

Concentration: 1.5%

Hydrocortisone is a low-potency topical corticosteroid identical to endogenous cortisol. It is the m…

Full Ingredient List (INCI)

  • Ruxolitinib Phosphate
  • Medium-Chain Triglycerides
  • Polyoxyl Stearate
  • Propylene Glycol
  • Stearyl Alcohol
  • Cetyl Alcohol
  • Light Mineral Oil
  • Methylparaben
  • Propylparaben
  • Edetate Disodium
  • Purified Water

Suitable Skin Types

SensitiveDryAll skin types (prescription use)

Key Features

  • First topical JAK inhibitor for dermatology
  • Non-steroidal mechanism of action
  • Approved for atopic dermatitis and vitiligo
  • Rapid itch relief
  • No skin atrophy risk
  • Novel class of therapy

Usage

Apply a thin layer to affected areas twice daily. Do not apply to more than 20% body surface area. Use for up to 8 weeks in AD, longer in vitiligo.

Available Sizes

60 g

Related Conditions

Atopic Dermatitis Topical JAK inhibitor for mild-to-moderate atopic dermatitis